Overview of endpoints in atrial fibrillation studies

被引:12
|
作者
Wyse, DG
机构
[1] Univ Calgary, Hlth Sci Ctr, Fac Med, Dept Cardiac Sci, Calgary, AB T2N 4N1, Canada
[2] Univ Calgary, Libin Cardiovasc Inst Alberta, Calgary, AB T2N 4N1, Canada
关键词
atrial fibrillation; clinical trials; Endpoints;
D O I
10.1016/j.hrthm.2004.03.070
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Among the principles for selection of endpoints for trials of arrhythmia management, the most important is that the endpoint be clinically relevant. According to this principle. the endpoint must be closely related to the objective of therapy. In the case of atrial fibrillation. for too long it seems. it has been believed that the primary objective of therapy has been maintenance of sinus rhythm. However. it is important to recognize that maintenance of sinus rhythm is. in fact, a surrogate endpoint and. as the lesson of the Cardiac Arrhythmia Suppression Trial has taught us. arrhythmia suppression is not necessarily a good surrogate for clinical events of importance. The use of clinical events as endpoints is to be encouraged, but the problem is that these events occur with a low frequency in many patients with atrial fibrillation. Symptoms are a primary target of therapy and potentially, a good endpoint, but Good methodology for quantification of symptoms remains to be developed. Methodology for assessment of patient-perceived quality of life is more highly developed. Surrogate endpoints. such as measurement of sinus rhythm or heart rate control, have the dual problems that they have not been well calibrated with clinical events and they sometimes are overly precise. Other surrogates have not been investigated. Composite endpoints are potentially useful, and cost is an important endpoint. More research on the validity of some of these endpoints is needed if we are to advance our knowledge of the management of atrial fibrillation in a meaningful way. (C) 2004 Heart Rhythm Society. All rights reserved.
引用
收藏
页码:B3 / B7
页数:5
相关论文
共 50 条
  • [1] Overview of endpoints in atrial fibrillation studies - Questions and answers
    Crijns
    Wyse
    Zipes
    Ruskin
    HEART RHYTHM, 2004, 1 (02) : B7 - B7
  • [2] Selection of endpoints in atrial fibrillation studies
    Wyse, DG
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2002, 13 (01) : S47 - S52
  • [3] Atrial fibrillation endpoints: Hospitalization
    Ruskin, JN
    Singh, JP
    HEART RHYTHM, 2004, 1 (02) : B31 - B34
  • [4] Endpoints for ablation of atrial fibrillation
    Stevenson, WG
    Epstein, LM
    HEART RHYTHM, 2006, 3 (02) : 146 - 147
  • [5] Diagnostic information in implantable devices that pertain to endpoints in atrial fibrillation studies
    Mehra, R
    Ziegler, P
    Koehler, J
    HEART RHYTHM, 2004, 1 (02) : B64 - B69
  • [6] Expert opinion on design and endpoints for studies on catheter ablation of atrial fibrillation
    Lewalter, Thorsten
    Blomstroem-Lundqvist, Carina
    Lakkireddy, Dhanunjaya
    Packer, Douglas
    Kuniss, Malte
    Meyer, Ralf
    Ladwig, Karl-H.
    Jilek, Clemens
    Diener, Hans-C.
    Boriani, Giuseppe
    Turakhia, Mintu P.
    Schneider, Steffen
    Svennberg, Emma
    Albers, Bert
    Andrade, Jason G.
    de Melis, Mirko
    Brachmann, Johannes
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2024, 35 (11) : 2182 - 2201
  • [7] Alternative endpoints for mortality in studies of patients with atrial fibrillation: The AFFIRM study experience
    Wyse, DG
    Slee, A
    Epstein, AE
    Gersh, BJ
    Rocco, T
    Vidaillet, H
    Volgman, A
    Weiss, R
    Shemanski, L
    Greene, HL
    HEART RHYTHM, 2004, 1 (05) : 531 - 537
  • [8] Sample size estimates for atrial fibrillation endpoints
    Warman, EN
    Grammatico, A
    Padeletti, L
    HEART RHYTHM, 2004, 1 (02) : B58 - B62
  • [9] Atrial fibrillation endpoints: Hospitalization - Questions and answers
    Mehra
    Ruskin
    Pritchett
    Newman
    Gillis
    Wyse
    Zipes
    HEART RHYTHM, 2004, 1 (02) : B34 - B35
  • [10] Defining endpoints in clinical trials on atrial fibrillation
    Camm, A. John
    Reiffe, James A.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2008, 10 (0H) : H55 - H78